Public market insider buying at ESSA Pharma (V:EPI)

Franklin Milan Berger, a Director, acquired 93,617 Common Shares on a direct ownership basis at prices likely ranging from US$6.986 to US$7.100 between August 19th, 2020 and August 21st, 2020.

ESSA Pharma is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

ESSA Pharma, Inc. is a Canada-based pharmaceutical company. The Company is focused on developing therapies for the treatment of castration-resistant prostate cancer (CRPC). It is developing EPI-7386 for the treatment of metastatic CRPC (mCRPC). It is also developing EPI-7386 combination therapy for mCRPC. In addition to this, the Company's pipeline also includes antien for triple negative androgen receptor (AR+) breast cancer. Its aniten compounds bind to the N-terminal domain of the androgen receptor (AR), inhibiting AR driven transcription and the AR signaling pathway in a manner which bypasses the drug resistance mechanisms associated with current anti-androgens. ESSA Pharma Inc. (EPI) has a high amount of executive buying compared to its small-cap peers in the market over the past three months. According to regulatory filings yesterday, one insider has invested a total amount of $658,676.